The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
 
Neal D. Shore
Employment - GenesisCare
Leadership - Alessa Therapeutics; Photocure
Consulting or Advisory Role - Abbvie; AIkido Pharma; Amgen; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Fize Medical; Foundation Medicine; Genesis Cancer Care; Genzyme; Guardant Health; ImmunityBio; Incyte; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myovant Sciences; Myriad Genetics; NGM Biopharmaceuticals; Nonagen Bioscience; Novartis; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; PlatformQ Health; Profound Medical; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion; Vessi Medical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring
Other Relationship - Alessa Therapeutics; Photocure
 
Hiroyuki Nishiyama
Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma; Janssen; Lilly; MSD
Speakers' Bureau - Astellas Pharma; Chugai Pharma; MSD
Research Funding - Astellas Pharma (Inst); Bayer Yakuhin (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Shahrokh F. Shariat
Stock and Other Ownership Interests - Seagen; Urogen pharma
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Cepheid; Dr. August Wolff GmbH & Co. KG Arzneimittel; Ferring; Ipsen; Janssen; MSD; Olympus; Pfizer; Pierre Fabre; Roche; Sanochemia; Sanofi; Urogen pharma
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Ribon Therapeutics; Roche; Sanochemia; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Ribon Therapeutics; Roche; Sanochemia; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent US07759077; Patent US20030054419; Patent US20030235816; Patent US2003235816
 
Gary Steinberg
Stock and Other Ownership Interests - Epivax Therapeutics; UroGen pharma
Consulting or Advisory Role - Abbvie; Aduro Biotech; Anchiano; Astellas Pharma; AstraZeneca; Boston Scientific; Bristol Myers Squibb Foundation; CG Oncology; CicloMed; Combat Medical; Dendreon; enGene; Epivax Therapeutics; FerGene; Ferring; Fidia Farmaceutici S. p. A.; FKD Therapies; Heat Biologics; IPSEN,; Janssen; MDxHealth; Merck; Natera; Nucleix; Pfizer; Photocure; Protara Therapeutics; Regeneron; Roche/Genentech; Seagen; Sesen Bio; Stimit; Taris BioMedical/Janssen; UroGen pharma; Verity Pharmaceuticals; Vyriad; xCures
Other Relationship - Bristol-Myers Squibb; CG Oncology; Fidia Pharma USA; Janssen; Merck KGaA; Pfizer; PhotoCure; Protara Therapeutics; Seagen
 
Ashish M. Kamat
Honoraria - AstraZeneca (I); Tesaro (I)
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; Biological Dynamics; Bristol-Myers Squibb; CG Oncology; Cystotech; Eisai; EnGeneIC; FerGene; Imagin Medical; Imvax; Incyte; Janssen; Medac; Merck; Nonagen Bioscience; Pfizer; Photocure; Protara Therapeutics; Roche; Seagen; Sesen Bio; Theralase; TMC Innovation; Urogen pharma; US Biotest
Research Funding - Adolor; Bristol-Myers Squibb; FKD Therapies; Heat Biologics; Janssen/Taris; Merck; NIH; Patient-Centered Outcomes Research Institute (PCORI); Photocure; Seagen; SWOG; Taris BioMedical; The Leo & Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - European Urology Oncology; International Bladder Cancer Group (IBCG); International Bladder Cancer Network; Journal of Urology; UroToday
 
Shaheen Riadh Alanee
Leadership - IncellDx
Stock and Other Ownership Interests - IncellDx
Consulting or Advisory Role - AstraZeneca; IncellDx; Merck
Speakers' Bureau - AstraZeneca
Research Funding - Merck
 
Kijoeng Nam
Employment - Merck
Stock and Other Ownership Interests - Merck Animal Health
 
Kentaro Imai
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Ekta Kapadia
Employment - Merck Animal Health
Stock and Other Ownership Interests - Merck
 
Noah M. Hahn
Honoraria - MedScape
Consulting or Advisory Role - AstraZeneca; ImmunityBio; Incyte; Janssen; Merck; Mirati Therapeutics; Natera; Pfizer; Pfizer/EMD Serono; Protara Therapeutics; Seattle Genetics/Astellas; Verity Pharmaceuticals
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); EMD Serono/Merck (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Ikena Oncology (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Seattle Genetics/Astellas (Inst)